Ondansetron is a selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with anti-emetic activity. The effect of Ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5-HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in postoperative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.
Novatron™ 8 mg Tablet: Each film-coated tablet contains Ondansetron Hydrochloride USP equivalent to 8 mg Ondansetron.
Novatron™ 8 mg/4 ml i.m./i.v. Injection: Each 4 ml ampoule contains Ondansetron Hydrochloride USP equivalent to 8 mg Ondansetron.